Diagnostik und Therapie der
akuten myeloischen Leukämie

M Bornhäuser; G Ehninger

doi:10.1055/s-0029-1237534

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2009; 134(39): 1935-1941
DOI: 10.1055/s-0029-1237534

Aktuelle Diagnostik & Therapie | Review article

Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Diagnostik und Therapie der akuten myeloischen Leukämie

Diagnostics and therapy of acute myeloid leukemiaM. Bornhäuser¹ , G. Ehninger¹

¹Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden

Abstract

Schlüsselwörter

akute myeloische Leukämie - risikostratifizierte Therapie

Keywords

acute myeloid leukemia - risk-adapted therapy

Full Text

References

Literatur

1 Bacher U, Badbaran A, Fehse B. et al . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol. 2009; 37 135-142
2 Bennett J M, Catovsky D, Daniel M T. et al . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33 451-458
3 Buchner T, Hiddemann W, Wormann B. et al . Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999; 93 4116-4124
4 Cornelissen J J, van Putten W L, Verdonck L F. et al . Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood. 2007; 109 3658-3666
5 Cornely O A, Maertens J, Winston D J. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356 348-359
6 Craig F E, Foon K A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008; 111 3941-3967
7 Hegenbart U, Niederwieser D, Sandmaier B M. et al . Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24 444-453
8 Marcucci G, Mrozek K, Ruppert A S. et al . Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004; 22 2410-2418
9 Platzbecker U, Thiede C, Fussel M. et al . Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006; 20 707-714
10 San Miguel J F, Martinez A, Macedo A. et al . Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997; 90 2465-2470
11 Schetelig J, Bornhauser M, Schmid C. et al . Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008; 26 5183-5191
12 Schlenk R F, Dohner K, Krauter J. et al . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358 1909-1918
13 Schmid C, Schleuning M, Schwerdtfeger R. et al . Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006; 108 1092-1099
14 Stelljes M, Bornhauser M, Kroger M. et al . Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005; 106 3314-3321
15 Thiede C, Steudel C, Mohr B. et al . Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99 4326-4335
16 Vardiman J W, Thiele J, Arber D A. et al . The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114 937-951

Prof. Dr. med. Martin Bornhäuser

Med. Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus

Fetscherstr. 74

01307 Dresden

Phone: 0351/458-4704

Fax: 0351/458-5362

Email: martin.bornhaeuser@uniklinikum-dresden.de